Life Scientist > Biotechnology

Premier subsidiary to go ahead with lung device

20 September, 2005 by Helen Schuller

Premier Bionics (ASX:PBI) subsidiary Pulmosonix will continue with the development of its PulmoScreen device which measures lung damage following the successful completion of a proof-of-concept trial.


Medical Therapies narrows focus, issues new prospectus

20 September, 2005 by Helen Schuller

Unable to secure sufficient funds with its first attempt at an IPO, Sydney-based Medical Therapies has issued a replacement prospectus which CEO Llewellyn Casbolt believes has "uncluttered and demystified the company and its technologies".


Eqitx, Mimotopes sign partnering deal

19 September, 2005 by Ruth Beran

Eqitx (ASX:EQX) and PharmAust (ASX:PAA) subsidiary Mimotopes have signed a partnership deal to jointly develop new targets for therapeutic or diagnostic approaches.


Cryptome to chase opps in vascular field

19 September, 2005 by Helen Schuller

Melbourne biopharma Cryptome Pharmaceuticals (ASX:CRP) has signed a collaboration agreement with the University of Virginia for the further discovery of compounds to treat 'vascular leak' -- a major component of inflammatory disorders and tissue damage associated with stroke, heart attacks and MS.


EvoGenix licenses leukaemia antibody

19 September, 2005 by Ruth Beran

Antibody developer EvoGenix (ASX:EGX) has signed a licensing deal with Dinona for one of the South Korean biotech's anti-leukaemia antibodies.


CogState turns focus from biotech

19 September, 2005 by Helen Schuller

Melbourne-based CogState (ASX:CGS) has distanced itself from the biotech sector, in a move that CEO Peter Bick described as "bowing to popular pressure that biotechs are highly risky and expensive businesses".


Avastra files for new BioWeld patent

16 September, 2005 by Ruth Beran

Sydney-based Avastra (ASX:AVS) has filed a provisional patent on the use of its BioWeld technology in conjunction with surgical glues and adhesives.


Starpharma investee Dimerix raises $1m

16 September, 2005 by Helen Schuller

Dimerix Bioscience has closed a series A capital raising worth almost AUD$1 million, and has revealed plans to accelerate the development of its new compounds created by applying its technologies to novel G-protein coupled receptor (GPCR) cluster targets.


Biota confirms Relenza orders from US, France, Hong Kong

16 September, 2005 by Ruth Beran

Melbourne-based Biota Holdings (ASX:BTA) has confirmed that three more countries have placed orders for Relenza, the anti-flu drug developed by Biota and commercialised by Britain's GlaxoSmithKline (GSK).


Out, damned spot: wheat disease faces genetic nemesis

16 September, 2005 by Graeme O'Neill

Wheat stem rust, an inexorable pathogen of Australia's wheat belt since 1925, is destined to be run over by the genetic equivalent of a four-decker bus.


Avastra abandons BioWeld Tube clinical trials

13 September, 2005 by Ruth Beran

Biomaterials company Avastra (ASX:AVS) is to abandon a clinical trial of its BioWeld Tube at Concord Repatriation and General Hospital, Sydney.


Antisense pleased with animal study of eye treatment

13 September, 2005 by Helen Schuller

Antisense Therapeutics (ASX:ANP) has claimed successful results from animal studies targeting the growth hormone receptor with an antisense drug, designed to reduce the growth of new blood vessels that can lead to two eye diseases which are major causes of blindness.


Polartechnics CEO wants profits this year

13 September, 2005 by Ruth Beran

After a turbulent year, Sydney-based Polartechnics (ASX:PLT) has seen a threefold increase in sales revenue for the 2004-05 financial year and is aiming to be profitable in the current year.


Peptech signs manufacturing deal

13 September, 2005 by Graeme O'Neill

Sydney antibody therapeutics developer Peptech (ASX:PTD) has signed an agreement with an unnamed biopharmaceuticals manufacturer to make its potent anti-inflammatory domain antibody (dAb) for preclinical and human clinical trials.


Unconfirmed Dutch order for Relenza boosts Biota

12 September, 2005 by Ruth Beran

Shares in Melbourne-based biopharma Biota Holdings (ASX:BTA) rose today in the wake of media reports that Holland has placed an order for Relenza, the anti-flu drug developed by Biota and commercialised by GlaxoSmithKline (GSK).


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd